Address: Sanofi-Aventis Deutschland GmbH
Industriepark Höchst, K703
65926 Frankfurt
,Germany
Tel: 0180 / 2 222010
Web: http://www.sanofi.de/l/de/de/index.jsp
The Sanofi-Aventis Deutschland GmbH is the German subsidiary of one of the world’s leading pharmaceutical companies. The Group employs approximately 100,000 employees worldwide and maintains strong market positions in the regions of North America, Europe and Asia. Its core business is the original innovative prescription drugs for the treatment (drugs) and prevention (vaccines) of serious, widespread diseases. The R & D expenditures by sanofi-aventis in 2008 amounted to 4.6 billion euros, of which, the Sanofi-Aventis Deutschland GmbH about 600 million euros worn. But not only the high use of resources is decisive – the research from sanofi-aventis is one of the most productive and successful worldwide. Currently, sanofi-aventis 65 novel drugs and vaccines in development. Of these 27 projects are in advanced clinical stage III or in the admission process. The focus is on seven core therapeutic areas: diabetes / metabolism, cardiovascular, thrombosis, central nervous system, internal medicine, oncology and vaccines. In Germany, one of sanofi-aventis with sales (including export) of 4.0 billion euros of the leading providers of innovative medicines.
Oskar Möbert, vice president of Veeva OpenData, discusses how standardizing customer reference data and systems organization-wide can help biopharmas scale globally and become more agile in their business. Data…
The biggest pharma industry and healthcare stories from Germany, including the country’s legalisation of cannabis; the MASH potential of Boehringer Ingelheim’s obesity candidate; Bayer’s further share price drop and expansion…
Pharma is rushing to adopt AI-driven tools in the hope of revolutionizing everything from drug discovery to clinical trials, regulatory submissions, and marketing efforts. While AI is the technology du…
Susanne Schaffert’s over 20-year stint at Novartis culminated with her presidency of the Swiss giant’s global oncology division, but when the company underwent a major restructure in 2022, she found…
As head of digital transformation at Bayer, Saskia Steinacker is well placed to unpack the hype around artificial intelligence in healthcare. In a wide-ranging interview, she explains how AI is…
Rainer Westermann of venture capitalist coalition Life Sciences Acceleration Alliance reviews the potential impact of the EU’s general pharmaceutical legislation on the investment climate for the EU life sciences sector.…
The latest pharma industry news from Germany, including Lilly’s new German plant; Bayer’s aborted anti-clotting drug trial and legal worries; Boehringer Ingelheim’s acquisition of Swiss biotech T3 Pharmaceuticals, and Hermes…
After positions at Novartis and Merck, Bettina Bauer, a trained scientist, joined Gilead in 2019 as VP and general manager of its German affiliate. Today, as the VP of the…
Merck’s Kaushal Kishore attempts to illustrate why pharma companies have struggled to crack what he calls “the Gross to Net (GtN) code.” He outlines the maturity journey for a pharma…
Patents can be an excellent way to demonstrate value, not only showing that a technology is protected but also how promising it can be when it eventually comes to market.…
The rise of niche therapies is shaping a more tailored engagement model, driven by data and AI, writes Florian Schnappauf, vice president of enterprise commercial strategy at Veeva Europe. …
Following the COVID-19 pandemic and the resulting supply chain disruptions, global drug pricing and access reforms have multiplied. The Inflation Reduction Act (IRA) has been introduced in the US while…
See our Cookie Privacy Policy Here
